Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FWY003 in Geographic Atrophy Secondary to AMD
NCT07441642Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Mar 2026
- Primary completion
- Aug 2029
- Modality
- Antibody Fragments, Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 2 trial of FWY003 in geographic atrophy (GA), sponsored by Novartis. Started Mar 2026; status: recruiting.
02
Drugs
FWY003
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT07441642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441642.